Julphar to open new plants
United Arab Emirates: Monday, March 17 - 2008 at 13:56
Ras Al Khaimah- based Gulf Pharmaceutical Industries (Julphar) announced it will open two plants in April to produce antibiotics, reported WAM. The Dhs30m plants are expected to produce over 50 kinds of antibiotics in phase 1 with a total capacity of 30 million syringes a year. Work is in progress for Julphar's 7 new manufacturing plants with a total cost of Dhs800m.
- ADD ARTICLE TO
-
Facebook
del.icio.us
Digg">
Also consider reading:
- » Sex pills sold over the counter
- » Healthcare for all in Qatar
- » BinSina launches hi-tech health campaign
- » Smiline opens in Dubai
- » UAE requires dentists to hire nurses
- » Pfizer to set up UAE research centre
- » Oman's pharmaceutical market looks bright
- » Oman to build $1bn healthcare city
- » Healthy bones campaign launched
- » e-TQM offers health masters course
Medilyn Manibo, Assistant News EditorMonday, March 17 - 2008 at 13:56 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Index : Healthcare
Browse related articles
Browse related articlesToday's most read articles:
Most read articles the past week:
Disclaimer:
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
Web Feeds